<?xml version='1.0' encoding='utf-8'?>
<document id="23700368"><sentence text="Clinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases." /><sentence text="Drug-drug interactions are an important therapeutic challenge among human immunodeficiency virus-infected patients" /><sentence text=" Early recognition of drug-drug interactions is important, but conflicts do exist among drug compendia on drug interaction information" /><sentence text=" We aimed to evaluate the consistencies of two drug information resources with regards to the severity rating and categorization of the potential interactions between antiretroviral and co-prescribed drugs" /><sentence text="" /><sentence text="We reviewed the case files of human immunodeficiency virus-infected children who were receiving treatment at the human immunodeficiency virus (HIV) clinic of the Lagos University Teaching Hospital, Idi Araba, between January 2005 and December 2010" /><sentence text=" All of the co-prescribed and antiretroviral drug pairs were screened for potential interactions using the Medscape Drug Interaction Checker and the Monthly Index of Medical Specialties Interaction Checker" /><sentence text=" Drug-drug interaction (DDI) severity and categorization were rated on a scale of A (no known interaction); B (minor/no action needed); C (moderate/monitor therapy); D (major/therapy modification); and X (contraindicated/avoid combination)" /><sentence text="" /><sentence text="A total of 280 patients were at risk of 596 potential DDIs" /><sentence text=" The databases showed discrepancies, with Medscape database identifying 504 (84" /><sentence text="6%) and USA MIMS database identifying 302 (50" /><sentence text="7%) potential DDIs" /><sentence text=" Simultaneous identification of DDIs by both databases occurred for only 275 (46" /><sentence text="1%) listed interactions" /><sentence text=" Both databases have a weak correlation on the severity rating (rs = 0" /><sentence text="45; P &lt; 0" /><sentence text="001)" /><sentence text=" The most common DDIs identified by the databases were nevirapine and artemisinin-based combination therapy (170; 28"><entity charOffset="55-65" id="DDI-PubMed.23700368.s19.e0" text="nevirapine" /><entity charOffset="70-81" id="DDI-PubMed.23700368.s19.e1" text="artemisinin" /><pair ddi="false" e1="DDI-PubMed.23700368.s19.e0" e2="DDI-PubMed.23700368.s19.e0" /><pair ddi="false" e1="DDI-PubMed.23700368.s19.e0" e2="DDI-PubMed.23700368.s19.e1" /></sentence><sentence text="5%), nevirapine and fluconazole (58; 9"><entity charOffset="5-15" id="DDI-PubMed.23700368.s20.e0" text="nevirapine" /><entity charOffset="20-31" id="DDI-PubMed.23700368.s20.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.23700368.s20.e0" e2="DDI-PubMed.23700368.s20.e0" /><pair ddi="false" e1="DDI-PubMed.23700368.s20.e0" e2="DDI-PubMed.23700368.s20.e1" /></sentence><sentence text="7%), and zidovudine and fluconazole (55; 9"><entity charOffset="9-19" id="DDI-PubMed.23700368.s21.e0" text="zidovudine" /><entity charOffset="24-35" id="DDI-PubMed.23700368.s21.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.23700368.s21.e0" e2="DDI-PubMed.23700368.s21.e0" /><pair ddi="false" e1="DDI-PubMed.23700368.s21.e0" e2="DDI-PubMed.23700368.s21.e1" /></sentence><sentence text="2%)" /><sentence text=" There were 272 (45" /><sentence text="6%) interaction severity agreements between the databases" /><sentence text="" /><sentence text="Discrepancies occurred in DDI listings between Medscape and USA MIMS databases" /><sentence text=" Health care professionals may need to consult more than one DDI information database to ensure safe concomitant prescribing for HIV patients" /><sentence text="" /></document>